news
AstraZeneca’s Forxiga approved in EU to treat chronic heart failure
The European Commission has approved Forxiga (dapagliflozin) for use in the EU to treat symptomatic chronic heart failure with reduced ejection fraction.
List view / Grid view
heart failure
article
NDMA: a recall trigger for the drug development industry
Product recalls due to contamination issues can be extremely costly for companies, in addition to the associated health implications. In this article, Marc Baiget Francesch explores the potential risks associated with N-nitrosodimethylamine (NDMA) contamination, why is it such a frequent contaminant and how to detect and eliminate the risks.
news
Fast Track designation given to heart failure treatment
Farxiga (dapagliflozin) has been given Fast Track designation by the FDA to reduce the risk of cardiovascular death.
news
FDA finds another carcinogenic impurity in ARB blood pressure drug
FDA is 'deeply concerned' about a third type of nitrosamine impurity detected in angiotensin II receptor blocker (ARB) medicines...
news
Cardiac cells integrated into microneedle patches could treat heart attacks
A tiny microneedle patch could be the future of delivering therapeutic cell related drugs to the heart of patients after a heart attack...
news
FDA updates on voluntary valsartan recalls
The FDA has provided guidance on valsartan recalls that have been occuring recently, providing lists of drugs affected, and methods of impurity testing...
news
Impurity in valsartan leads to voluntary recall
Some drugs with active ingredient valsartan have been recalled due to presence of impurity NMDA...
news
ITI-214 Parkinson’s drug may be useful for heart failure patients
A drug currently in trials for Parkinson's disease has shown promise in treating heart failure, without the risk of dangerous side effects...
news
Calcium PET/CT testing in coronary arteries predicts heart attack risk
Researchers have found that incorporating imaging technologies more precisely can predict heart attack risk...
news
Aspirin lowers risk of death for patients with diabetes and heart failure
Researchers assess aspirin as a preventive measure for patients who have both diabetes and heart failure...
news
Heart failure market worth $16 billion by 2026 as Novartis’ drug triggers growth
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, representing an impressive compound annual growth rate of 15.7%, according to research and consulting firm…
news
AstraZeneca enters agreement with Recordati for Seloken in Europe
24 May 2017 | By Niamh Marriott, Junior Editor
AstraZeneca has entered into an agreement with Recordati for the commercial rights to Seloken/Seloken ZOK treatments in Europe...
news
EU funds stem cell technologies for heart repair – Eppendorf is project partner
5 September 2016 | By Eppendorf
Within the EU Research and Innovation program Horizon 2020 the European Union is now funding the TECHNOBEAT research project with almost 6 million Euro...
news
Heart failure treatment market to rise to $11.8 billion
4 May 2016 | By Victoria White, Digital Content Producer
The heart failure treatment market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, according to research and consulting firm GlobalData.
news
NICE recommends heart failure drug Entresto
27 April 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Entresto (sacubitril valsartan) for some people with heart failure.
